Nektar Therapeutics Beats on Both Top and Bottom Lines
Nektar Therapeutics (NAS: NKTR) reported earnings on Aug. 9. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended June 30 (Q2), Nektar Therapeutics beat expectations on revenue and exceeded expectations on earnings per share.
Compared to the prior-year quarter, revenue increased significantly and GAAP loss per share shrank.
Margins grew across the board.
Nektar Therapeutics chalked up revenue of $23.7 million. The seven analysts polled by S&P Capital IQ expected to see a top line of $20.1 million on the same basis. GAAP reported sales were 37% higher than the prior-year quarter's $17.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.30. The five earnings estimates compiled by S&P Capital IQ predicted -$0.33 per share. GAAP EPS were -$0.30 for Q2 compared to -$0.32 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 69.6%, 1,660 basis points better than the prior-year quarter. Operating margin was -114.0%, 8,370 basis points better than the prior-year quarter. Net margin was -144.8%, 6,510 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $21.3 million. On the bottom line, the average EPS estimate is -$0.41.
Next year's average estimate for revenue is $87.1 million. The average EPS estimate is -$1.47.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 192 members out of 220 rating the stock outperform, and 28 members rating it underperform. Among 48 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 37 give Nektar Therapeutics a green thumbs-up, and 11 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Nektar Therapeutics is outperform, with an average price target of $10.88.
- Add Nektar Therapeutics to My Watchlist.
The article Nektar Therapeutics Beats on Both Top and Bottom Lines originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.